Prevention    Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers J Am Coll Cardiol (2008) 51; 1742-8 H. Yasue, Y. Mizuno, E. Harada, T. Itoh, H. Nakagawa, M. Nakayama, H. Ogawa, S. Tayama, T. Honda, S. Hokimoto, S. Ohshima, Y. Hokamura, K. Kugiyama, M. Horie, M. Yoshimura, M. Harada, S. Uemura and Y. Saito The relationship between obesity and atherosclerotic progression and prognosis among patients with coronary artery bypass grafts the effect of aggressive statin therapy J Am Coll Cardiol (2008) 52; 620-5 C. C. Wee, S. Girotra, A. R. Weinstein, M. A. Mittleman and K. J. Mukamal Simulation-based education improves quality of care during cardiac arrest team responses at an academic teaching hospital: a case-control study Chest (2008) 133; 56-61 D. B. Wayne, A. Didwania, J. Feinglass, M. J. Fudala, J. H. Barsuk and W. C. McGaghie Comparison of low-fat versus Mediterranean-style dietary intervention after first myocardial infarction (from The Heart Institute of Spokane Diet Intervention and Evaluation Trial) Am J Cardiol (2008) 101; 1523-30 K. R. Tuttle, L. A. Shuler, D. P. Packard, J. E. Milton, K. B. Daratha, D. M. Bibus and R. A. Short Community-based provision of statin and aspirin after the detection of coronary artery calcium within a community-based screening cohort J Am Coll Cardiol (2008) 51; 1337-41 A. J. Taylor, J. Bindeman, I. Feuerstein, T. Le, K. Bauer, C. Byrd, H. Wu and P. G. O'Malley Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association J Am Coll Cardiol (2009) 53; 298-304 J. S. Skyler, R. Bergenstal, R. O. Bonow, J. Buse, P. Deedwania, E. A. Gale, B. V. Howard, M. S. Kirkman, M. Kosiborod, P. Reaven and R. S. Sherwin Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery J Am Coll Cardiol (2008) 51; 1938-43 S. J. Shah, D. D. Waters, P. Barter, J. J. Kastelein, J. Shepherd, N. K. Wenger, D. A. DeMicco, A. Breazna and J. C. LaRosa Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women J Am Coll Cardiol (2008) 51; 997-1002 R. Rossi, A. Nuzzo, G. Origliani and M. G. Modena Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study) Circulation (2008) 117; 494-502 K. Mizuno, N. Nakaya, Y. Ohashi, N. Tajima, T. Kushiro, T. Teramoto, S. Uchiyama and H. Nakamura Increased serum levels and expression of S100A8/A9 complex in infiltrated neutrophils in atherosclerotic plaque of unstable angina Heart (2008) 94; 1002-7 S. Miyamoto, M. Ueda, M. Ikemoto, T. Naruko, A. Itoh, S. Tamaki, R. Nohara, F. Terasaki, S. Sasayama and M. Fujita Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients J Am Coll Cardiol (2008) 52; 1769-81 E. J. Mills, B. Rachlis, P. Wu, P. J. Devereaux, P. Arora and D. Perri Impact of statin use on outcomes after coronary artery bypass graft surgery Circulation (2008) 118; 1785-92 A. Kulik, M. A. Brookhart, R. Levin, M. Ruel, D. H. Solomon and N. K. Choudhry Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation (2008) 117; 3002-9 J. J. Kastelein, W. A. van der Steeg, I. Holme, M. Gaffney, N. B. Cater, P. Barter, P. Deedwania, A. G. Olsson, S. M. Boekholdt, D. A. Demicco, M. Szarek, J. C. LaRosa, T. R. Pedersen and S. M. Grundy The impact of prevention on reducing the burden of cardiovascular disease Circulation (2008) 118; 576-85 R. Kahn, R. M. Robertson, R. Smith and D. Eddy Fatal and Nonfatal Cardiovascular Disease and the Use of Therapies for Secondary Prevention in a Rural Region of India Circulation (2009) R. Joshi, C. K. Chow, P. K. Raju, R. Raju, K. S. Reddy, S. Macmahon, A. D. Lopez and B. Neal Association of the 719Arg variant of KIF6 with both increased risk of coronary events and with greater response to statin therapy J Am Coll Cardiol (2008) 51; 2195; author reply 95-6 O. Iakoubova, J. Shepherd and F. Sacks Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention Circulation (2009) 119; 902-7 W. S. Harris, D. Mozaffarian, E. Rimm, P. Kris-Etherton, L. L. Rudel, L. J. Appel, M. M. Engler, M. B. Engler and F. Sacks Promise of low-density lipoprotein-lowering therapy for primary and secondary prevention Circulation (2008) 117; 569-73; discussion 73 S. M. Grundy Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk Circulation (2008) 117; 2875-83 J. P. Greving, E. Buskens, H. Koffijberg and A. Algra Defining a rational approach to screening for cardiovascular risk in asymptomatic patients J Am Coll Cardiol (2008) 52; 330-2 P. Greenland and D. Lloyd-Jones Clinical and angiographic follow-up of small vessel lesions treated with paclitaxel-eluting stents (from the TRUE Registry) Am J Cardiol (2008) 102; 1002-8 C. Godino, S. Furuichi, A. Latib, N. Morici, A. Chieffo, E. Romagnoli, C. Tamburino, R. Barbagallo, M. Cera, D. Antoniucci, O. Goktekin, C. Di Mario, B. Reimers, E. Grube, F. Airoldi, G. M. Sangiorgi and A. Colombo Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors J Am Coll Cardiol (2008) 51; 2040-4 C. Gazzaruso, S. B. Solerte, A. Pujia, A. Coppola, M. Vezzoli, F. Salvucci, C. Valenti, A. Giustina and A. Garzaniti The role of aspirin in cardiovascular prevention: implications of aspirin resistance J Am Coll Cardiol (2008) 51; 1829-43 A. Y. Gasparyan, T. Watson and G. Y. Lip Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study J Am Coll Cardiol (2008) 52; 24-32 S. H. Choi, A. Chae, E. Miller, M. Messig, F. Ntanios, A. N. DeMaria, S. E. Nissen, J. L. Witztum and S. Tsimikas Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden Circulation (2008) 117; 2458-66 C. M. Ballantyne, J. S. Raichlen, S. J. Nicholls, R. Erbel, J. C. Tardif, S. J. Brener, V. A. Cain and S. E. Nissen Efficacy of in-hospital multidimensional interventions of secondary prevention after acute coronary syndrome: a systematic review and meta-analysis Circulation (2008) 117; 3109-17 R. Auer, J. Gaume, N. Rodondi, J. Cornuz and W. A. Ghali Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial J Am Coll Cardiol (2009) 53; 720-9 D. Atar, P. Petzelbauer, J. Schwitter, K. Huber, B. Rensing, J. D. Kasprzak, C. Butter, L. Grip, P. R. Hansen, T. Suselbeck, P. M. Clemmensen, M. Marin-Galiano, B. Geudelin and P. T. Buser In search of the "vulnerable plaque": can it be localized and will focal regional therapy ever be an option for cardiac prevention J Am Coll Cardiol (2008) 51; 1539-42 J. A. Ambrose